secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001736730-25-000092
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.
- Private placement initially closed $50M with potential proceeds up to $100M to fund CMP-002.
- Initiated GLP toxicology studies for CMP-002; Phase 1/2 trial expected as early as H2 2026.
- Strategic decision to pursue partnership for further development of CMP-001 (urea cycle disorders).
- Net loss $15.1M for Q3 2025 vs $13.5M for Q3 2024; R&D expenses $9.4M, G&A $4.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/0001736730-25-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/camp-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer